Breakthrough Drug Doubles Survival in Pancreatic Cancer

Scientists have cracked a decades-old barrier in pancreatic cancer treatment with a new drug, daraxonrasib, that targets the notorious KRAS mutation—once deemed “undruggable.” In a landmark trial of 500 advanced patients, the drug nearly doubled survival from 6.5 to over 13 months, slashed death risk by 60%, and offered fewer debilitating side effects than chemo. With FDA expedited approval likely, this breakthrough could redefine cancer therapy—offering hope where there was once little. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/d492ec2f5253b54c